Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 269 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open surgical repair Clear all

Conditions: Osteoarthritis
Interventions: Liposuction with Local Anesthesia, Intra articular infusion of AD-SVF; Procedure · Biological
Lead sponsor: Ageless Regenerative Institute; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Aortic Aneurysm, Thoracoabdominal
Interventions: Physician-modified aortic endograft; Device
Lead sponsor: Yale University; Other
Eligibility: 50 Years to 95 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 2
States / cities: New Haven, Connecticut • Lebanon, New Hampshire

Conditions: Mitral Valve Regurgitation
Interventions: Mitral valve repair, Transcatheter edge-to-edge repair; Procedure · Device
Lead sponsor: Annetine Gelijns; Other
Eligibility: 60 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 28
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 19 more

Conditions: Ventral Hernia
Interventions: Group 1; Device
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Asheville, North Carolina • Charlotte, North Carolina • Greenville, South Carolina

Conditions: Abdominal Aortic Aneurysm
Interventions: Endovascular AAA repair with InCraft®; Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: 20 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
Interventions: Synergy Ablation System; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 49
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 41 more

Conditions: Abdominal Aortic Aneurysm
Interventions: Resoundant Driver System; Device
Lead sponsor: Ohio State University; Other
Eligibility: 20 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Surgical Wounds, Mohs Surgery
Interventions: Topical Timolol, Normal Saline; Drug
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Ventral Incisional Hernia
Interventions: Elective Midline Laparotomy, Imaging: Ultrasound, Tensiometry; Procedure · Other
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Solid Tumours
Interventions: AZD4956, Saruparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: New York, New York • Providence, Rhode Island • Houston, Texas + 1 more

Conditions: Ventral Hernia, Inguinal Hernia
Interventions: Methocarbamol, Standard Opioid, Standard opioid plus methocarbamol; Drug
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Symptomatic Functional MR 3 or Greater
Interventions: This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation.; Device
Lead sponsor: Valcare Medical Ltd.; Industry
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Phoenix, Arizona • La Jolla, California • Atlanta, Georgia + 8 more

Conditions: Metastatic Triple Negative Breast Cancer
Interventions: Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 17 more

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Pembrolizumab; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 13
States / cities: San Francisco, California • West Los Angeles, California • Washington D.C., District of Columbia + 10 more

Conditions: Ventral Hernia, Abdominal Hernia
Interventions: BOTOX Dose A, Placebo for BOTOX, BOTOX Dose B, BOTOX Dose C; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Mineola, New York • Charlotte, North Carolina

Conditions: Hernia, Incisional Hernia, Hernia, Inguinal, Indirect, Hernia, Inguinal, Direct, Inguinal Hernia
Interventions: Hernia repair; Procedure
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 18 Years and older
Enrollment: 944 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 17
States / cities: Beverly Hills, California • Nashville, California • Oakland, California + 14 more

Conditions: Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer, Rectal Adenocarcinoma, Endometrial Cancer
Interventions: ATX-559; Drug
Lead sponsor: Accent Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 2 more

Conditions: Open Abdomen, Abdominal Adhesions, Trauma, Wounds and Injury
Interventions: Seprafilm; Biological
Lead sponsor: Stan Stawicki; Other
Eligibility: 18 Years to 89 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Camden, New Jersey • Charlotte, North Carolina • Columbus, Ohio + 2 more

Conditions: MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Interventions: HRO761, pembrolizumab, irinotecan; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more

Conditions: Recurrent Endometrial Cancer
Interventions: Pembrolizumab, Lenvatinib; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ventral Hernia, Incisional Hernia
Interventions: Mesh placement with Transfascial Sutures; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Abdominal Aortic Aneurysm
Interventions: QUANTUM LP™ STENT GRAFT SYSTEM, Open surgical repair; Device · Procedure
Lead sponsor: Cordis US Corp.; Industry
Eligibility: 21 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Brain-derived Neurotrophic Factor (BDNF), Cognitive Function, Affect
Interventions: Whole Coffee Fruit Concentrate (WCFC), Nutrim; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.

Physician-Modified Fenestrated and Branched Aortic Endografting for TAAA

Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)

Microlyte in Prevention of SSI After Open Ventral Hernia Repair

A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)

ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation

Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms

The Effects of Timolol On Healing and Cosmesis of Mohs Scalp Wounds: An Open Label Trial

Shear-Wave Elastography

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Methocarbamol in Ventral and Inguinal HR

AMEND TS Early Feasibility Study

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique

A Prospective Study to Compare the Clinical Outcomes, Pain and Patient Quality of Life for Hernia Patients

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance

Randomized Control Trial Comparing Transfascial Suture for Mesh Fixation to No Mesh Fixation

Study of the Endovascular QUANTUM LP™ Stent Graft System in Abdominal Aortic Aneurysms (AAA)

Whole Coffee Fruit Concentrate Pilot Study 1